ESPE Abstracts (2022) 95 P1-108

ESPE2022 Poster Category 1 Growth and Syndromes (85 abstracts)

Efficacy, Observer-Reported Outcomes, and Safety of Once-Weekly Somapacitan in Children with Growth Hormone Deficiency (GHD): 4-Year Results from the REAL 3 Trial

Lars Sävendahl 1,2 , Tadej Battelino 3,4 , Michael Højby Rasmussen 5 , Meryl Brod 6 , Kai Wai Lee 7 , Paul Saenger 8 & Reiko Horikawa 9

43 views


1Department of Women’s and Children’s Health, Karolinska Institutet, Solna, Sweden; 2Pediatric Endocrinology Unit, Karolinska University Hospital, Solna, Sweden; 3Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; 4University Medical Center Ljubljana, Ljubljana, Slovenia; 5Clinical Drug Development, Novo Nordisk A/S, Søborg, Denmark; 6The Brod Group, Mill Valley, USA; 7Novo Nordisk Rare Disease, Novo Nordisk A/S, Søborg, Denmark; 8NYU Langone Health, Mineola, USA; 9National Center for Child Health and Development, Tokyo, Japan


Children with GHD are currently treated with daily subcutaneous growth hormone (GH) injections, which can be burdensome. Somapacitan is a long-acting GH derivative in development for once-weekly use in children with GHD. REAL 3 (NCT02616562) is a phase 2, multinational, randomised, open label, controlled trial assessing efficacy and safety of somapacitan vs daily GH (Norditropin®). Prepubertal, GH-naïve children with GHD received 0.04 (n=16), 0.08 (n=15) or 0.16 (n=14) mg/kg/week somapacitan, or 0.034 mg/kg/day daily GH for 1 year. In a 2-year safety extension, all patients on somapacitan (n=45) received 0.16 mg/kg/week; patients receiving daily GH remained on daily GH. In a 4 year safety extension, treatment switched to somapacitan 0.16 mg/kg/week in the daily GH group (daily GH/somapacitan, n=11) and remained unchanged in the somapacitan group (somapacitan/somapacitan, n=39). We present results from year 4, the first year of the 4 year safety extension. Data are mean (SD). Height velocity (HV) was 7.4 (1.6) cm/year for somapacitan/somapacitan and 6.6 (1.6) cm/year for daily GH/somapacitan, vs 8.3 (1.7) and 7.6 (2.0) cm/year for somapacitan/somapacitan and daily GH, respectively, at year 3. HV SD score (SDS) was 1.55 (1.70) and 0.88 (1.61) for daily GH/somapacitan; change in height SDS from baseline was 2.85 (1.25) and 2.28 (0.97); insulin-like growth factor-I SDS was 1.29 (1.23) and 0.94 (1.60) for somapacitan/somapacitan and daily GH/somapacitan, respectively. The Table shows overall scores of GHD child treatment burden (CTB) and GHD parent treatment burden (PTB), reported by parents/guardians. During year 4, 20 patients (51.3%) receiving somapacitan/somapacitan experienced 84 adverse events (AEs), and eight patients (72.7%) receiving GH/somapacitan experienced 12 AEs. Most AEs were mild/moderate and unrelated to treatment. Height-related outcomes were similar between and as expected for both treatment arms. Somapacitan may lead to improvement in treatment burden vs daily GH. Somapacitan safety profile was consistent with previous reports.

Table: GHD-treatment burden measures from years 2–4; mean (SD) scores (lower indicates improvement)
  Daily GH/somapacitan Somapacitan/somapacitan
  N=11 N=39/40 N=39 N=37/38
Year 2 3 4* 2 3 4
GHD-CTB 6.4 (8.2) 15.1 (16.3) 7.1 (9.4) 7.6 (9.4) 7.4 (6.8) 5.8 (7.5)
GHD-PTB 8.7 (10.9) 11.3 (16.4) 6.3 (12.2) 9.5 (11.2) 9.6 (12.2) 8.7 (12.1)
*Patients switched after year 3.
Across physical, emotional wellbeing and interference domains.
Across emotional wellbeing and interference domains.

Volume 95

60th Annual ESPE (ESPE 2022)

Rome, Italy
15 Sep 2022 - 17 Sep 2022

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.